Un­der a new CEO, Ger­man CD­MO Viba­log­ics bets $150M and 110,000 square feet on the gene ther­a­py rev­o­lu­tion

Viba­log­ics start­ed out 18 years ago mak­ing vac­cines for chick­ens. Now they’re look­ing to dri­ve the gene and cell ther­a­py rev­o­lu­tion — and make a few Covid-19 shots on the way.

On Wednes­day, the Ger­man CD­MO an­nounced they’re in­vest­ing $150 mil­lion in­to a 110,000 square foot virus and vi­ral vec­tor man­u­fac­tur­ing fa­cil­i­ty in Boston, join­ing a wave of com­pa­nies try­ing to build the in­fra­struc­ture that can one day mass pro­duce the hun­dreds of gene and cell ther­a­pies now in biotech and Big Phar­ma pipelines across the globe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER